Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022
Journal of Clinical Oncology · 01.06.2024 · 42 (16) · 1953-1960
DOI: 10.1200/jco.23.01777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.06.2024. Verfasst von Hong Xiao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA. Hauptthemen laut MEDLINE: Brain Neoplasms, Patient Selection, Clinical Trials as Topic. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE In October 2017, an ASCO, Friends of Cancer Research (FoCR), and US Food and Drug Administration (ASCO/FoCR/FDA) task force recommended that common eligibility criteria be modified to make trials more inclusive. We examined whether patterns of exclusions regarding patients with brain metastases changed over time in relation to these recommendations. METHODS Trial eligibility criteria were abstracted from ClinicalTrials.gov for phase I-III US-based interventional clinical trials for patients with advanced breast, colorectal, lung, or melanoma cancers from January 2012 to December 2022. Trials were examined to determine whether patients with brain metastases were not excluded, conditionally excluded (ie, excluded in some circumstances), or wholly excluded. An interrupted time series analysis with multinomial logistic regression was used to determine whether the ASCO/FoCR/FDA recommendations were associated with changes in brain metastases criteria. RESULTS We evaluated N = 3,077 trials. Patients with brain metastases were not excluded in 506 trials (16.4%), conditionally excluded in 2,263 trials (73.5%), and wholly excluded in 308 trials (10.0%). In the postrecommendation period, we estimated a 68% increase in the odds of brain metastases not excluded compared with conditionally excluded (odds ratio, 1.68 [95% CI, 1.06 to 2.66], P = .03). The proportion of trials in which patients with brain metastases were not excluded increased (from 11.5% v 17.3%) and conditionally excluded decreased (from 82.3% to 75.2%, P = .03). We found no difference in the proportion of trials in which patients with brain metastases were wholly excluded (7.5% v 6.2%, P = .42). CONCLUSION The ASCO/FoCR/FDA task force recommendations were associated with a shift in patterns of brain metastases exclusion criteria from conditionally excluded to not excluded. These findings demonstrate that the cancer clinical trial community has begun to change the way trials are written to be more inclusive.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA.
- Columbia University Medical Center, New York City, NY.
ORCID-Profile: Hong Xiao, Riha Vaidya, Dawn L Hershman, Joseph M Unger
Förderung
- NCI NIH HHS
Zitieren
APA
Xiao, H., Vaidya, R., Hershman, D. L., & Unger, J. M. (2024). Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022. Journal of Clinical Oncology, 42(16), 1953-1960. https://doi.org/10.1200/jco.23.01777
Vancouver
Xiao H, Vaidya R, Hershman DL, Unger JM. Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022. Journal of Clinical Oncology. 2024;42(16):1953-1960. doi:10.1200/jco.23.01777
BibTeX
@article{Xiao2024,
author = {Xiao, Hong and Vaidya, Riha and Hershman, Dawn L and Unger, Joseph M},
title = {Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {16},
pages = {1953--1960},
doi = {10.1200/jco.23.01777}
}
EUVIMED